CoChat

Fecal Microbiota Transplantation in Ulcerative Colitis: Review of 24 Years Experience: 1644

Borody, Thomas, Wettstein, Antony, Campbell, Jordana, Leis, Sharyn, Torres, Margaux, Finlayson, Sarah, Nowak, Anna · 2012 · American Journal of Gastroenterology
Cited by 32

The DOI matches its Crossref record.

Abstract

Purpose: Fecal Microbiota Transplantation (FMT) has traditionally been employed in Clostridium difficile infection (CDI), achieving near 100% cure rates1. However, preliminary reports are emerging of FMT's reversal of idiopathic Ulcerative Colitis (UC)2. To date, analysis of remission rates and treatment response to FMT in UC have not been available. At CDD, FMT has been offered as a treatment option for patients with UC since 1988. We provide an analysis of this cohort of patients aimed at documenting the success rate of this therapy. Methods: A review of all UC patients who underwent FMT at our centre was conducted. UC diagnosis was confirmed clinically, endoscopically, and histologically. Patients with indeterminate colitis or Crohn's Disease were excluded from the analysis. Sixty-two patients (40M; m 42.3 +/- 11.5y: 22F m 48.45 +/- 16.49y) with active UC and follow-up results were included in the analysis. Clinical remission was defined as a 0-1 modified Powell-Tuck index and partial remission as a ≥2 point decrease. Non-response was defined as ≤2 point decrease, unchanged score, increase in score over two consecutive visits, surgical intervention, or FMT-related adverse event requiring treatment cessation. Results: Overall, 91.9% of patients responded to FMT. Of these, 67.7% of patients (42/62) achieved complete clinical remission, and 24.2% of patients (15/62) achieved partial response. The remaining 8% (5/62) were treatment failures. Improvement in CRP and ESR correlated with clinical response observed in FMT patients. Twenty-one patients underwent repeat colonoscopy with a mean time to follow-up of 33 mths (range 1-198 mths). Of these 12/21 (57.1%) were found to have profound mucosal healing with a normal mucosal appearance, return of vascular pattern and no histological inflammation, but in one patient scarring was seen in areas of previously severe inflammation. A further eight patients (8/21, 38.1%) achieved normalisation of mucosa but had some isolated areas of patchy, mild inflammation. One patient (1/21, 4.8%) had remaining active colitis. FMT was well tolerated and produced no significant adverse events. Conclusion: FMT achieves high response rates in UC, and can cure UC in a subset of patients. This should be followed with blinded trials and metagenomic analyses to establish protocols for successful remission in UC. This is the first analysis of UC response rates in relation to FMT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.14309/00000434-201210001-01644

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 32

Metadata

Authors
Borody, T., Wettstein, A., Campbell, J., Leis, S., Torres, M., Finlayson, S., & Nowak, A.
Venue
American Journal of Gastroenterology
Published
2012-10
Volume
107
Pages
S665
ISSN
0002-9270 (ISSN-L)
OpenAlex
W2978048032
Cited by
32
References
0
FWCI
2.48
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fecal Microbiota Transplantation in Ulcerative Colitis: Review of 24 Years Experience: 1644. https://app.cochat.ai/papers/10.14309/00000434-201210001-01644
The paper
Borody, T., Wettstein, A., Campbell, J., Leis, S., Torres, M., Finlayson, S., & Nowak, A. (2012). Fecal Microbiota Transplantation in Ulcerative Colitis: Review of 24 Years Experience: 1644. American Journal of Gastroenterology. https://doi.org/10.14309/00000434-201210001-01644

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.